Key result
Tamoxifen at concentrations up to 5 μM did not significantly reduce hERG1 potassium channel currents or gene expression in the MCF-7 breast cancer cell line compared to control.
Why the study?
Alterations in ion channel expression are implicated in breast cancer pathophysiology, but the impact of tamoxifen on hERG1 potassium channel expression remained to be elucidated.
Does tamoxifen reduce hERG1 potassium channel gene expression and currents in the MCF-7 cell line?
Does tamoxifen reduce hERG1 potassium channel gene expression and currents in the MCF-7 cell line?
Tamoxifen did not significantly block potassium channel currents or alter hERG1 gene expression in the MCF-7 breast cancer cell line.
No significant hERG effects from tamoxifen in MCF-7 cells; leaves open cardiac safety questions requiring in vivo confirmation.
Objective: Tamoxifen (TAM) is a nonstreroidal antiestrogenic pharmaceutical agent extensively employed in the therapeutic management of breast cancer. Alterations in the expression patterns of diverse ion channels have been implicated in the pathophysiology of breast cancer. The principal objective of this investigation was to elucidate the impact of TAM on the expression of the hERG1 potassium channel in the MCF-7 cell line. Methods: Cytotoxicity induced by TAM across various concentrations was assessed through the utilization of the MTT method. The patch clamp method was employed for electrophysiological analyses. The gene expression of the hERG1 potassium channel was quantified utilizing RT-qPCR. Results: The electrophysiological findings revealed reduction in potassium channel currents, reaching maximal inhibition at a TAM concentration of 5 μM. Concurrently, hERG1 potassium channel gene expression exhibited a decrease at the 5 μM TAM concentration. Despite statistical analysis, no statistically significant values were identified in both potassium channel currents and gene expression analyses when compared to the control group. Our results demonstrate that the blocking effect of TAM on potassium channel currents in the MCF-7 cell line was not determined. Conclusions: Further investigations are warranted to elucidate comprehensively the role of TAM in modulating hERG1 in breast cancer.
No takes yet. Share an insight, caveat, or question.
Eroğlu et al. (2024) studied Breast cancer (MCF-7 cell line). Tamoxifen vs. Control group was evaluated on hERG1 potassium channel gene expression and potassium channel currents. Tamoxifen at concentrations up to 5 μM did not significantly reduce hERG1 potassium channel currents or gene expression in the MCF-7 breast cancer cell line compared to control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: